Acidic and basic fibroblast growth factor levels in spinal cord cultures are not regulated by alterations in heparan sulfate proteoglycan expression.
The present study was undertaken to assess both the levels of acidic and basic fibroblast growth factors in spinal cord cultures and to determine how they were presented to responsive cells. Western blots detected a single acidic fibroblast growth factor-like protein (17 kDa) and two (18 kDa, 24 kDa) basic fibroblast growth factor-immunoreactive proteins, the levels of which varied with the antibody used. Levels of all three proteins were unaltered in cultures grown in the presence of a mitotic inhibitor, which greatly reduced the number of astrocytes. Cell blots showed increased survival of spinal cord neurons at Mr that corresponded with the three proteins detected immunologically. Solubilized cultures separated on a P100 column showed mitogenic activity for NIH3T3 cells from 17-18 and 24 kDa fractions. Treatment of the cultures with heparitinase did not decrease the levels of acidic and basic fibroblast growth factors detected by Western blots, suggesting that these proteins were not associated with extracellular membrane heparan sulfate proteoglycans. The major fraction of both proteins appeared to be intracellular with a minor amount complexed with extracellular matrix proteins. An inhibitor of xylose-linked proteoglycan synthesis significantly altered heparan sulfate proteoglycan deposition into extracellular matrix, but did not alter the levels of acidic or basic fibroblast growth factors detected by Western blots, or the levels of choline acetyltransferase, glutamic acid decarboxylase, or aspartate aminotransferase activities. These results indicate that both acidic and basic fibroblast growth factors are stored predominantly intracellularly, with only a minor fraction complexed with extracellular proteins. We suggest that these intracellular proteins may be released following injury in the CNS and mediate a cascade of neuroprotective events.
Whittemore
S R
SR
Miami Project, University of Miami School of Medicine, FL 33136.
White
L A
LA
Sanon
H R
HR
D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism; D003864:Depression, Chemical; D005110:Extracellular Space / Q000378:metabolism; D016220:Fibroblast Growth Factor 1 / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D005467:Floxuridine / Q000494:pharmacology; D006493:Heparin / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000737:chemistry; D006801:Humans; D007150:Immunohistochemistry; D008970:Molecular Weight; D009474:Neurons / Q000201:enzymology; D011485:Protein Binding; D011509:Proteoglycans / Q000096:biosynthesis* / Q000737:chemistry; D051381:Rats; D011919:Rats, Inbred Strains; D016622:Silver Staining; D013116:Spinal Cord / Q000378:metabolism*
D011508:Chondroitin Sulfate Proteoglycans; D011509:Proteoglycans; C036090:heparin proteoglycan; D005467:Floxuridine; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D006493:Heparin